Sandoz and Novartis Recall Prescription Drug Blister Packages Due to Failure to Meet Child-Resistant Closure Requirements

What was recalled

In July of 2018, a significant and somewhat unexpected recall was announced by the U.S. Consumer Product Safety Commission (CPSC) involving prescription medications manufactured by two major pharmaceutical companies: Novartis and Sandoz. While most people associate drug recalls with contamination or incorrect dosages, this particular action was triggered by the packaging itself. The firms recalled specific blister packages of their prescription drugs because these packages failed to meet the mandatory child-resistant closure requirements established by the Poison Prevention Packaging Act. This is a critical distinction; the medication inside the cards was not defective, but the outer shell designed to protect it from accidental ingestion by young children did not function as legally required.

The scope of this recall is quite broad, covering a variety of common and specialized medications. For Novartis, the affected products include Zofran ODT (ondansetron), which is frequently used to prevent nausea and vomiting, and Entresto (sacubitril/valsartan), a medication prescribed for heart failure. The Zofran packages come in 4 mg and 8 mg strengths, typically sold in cartons containing 30 count boxes made up of three cards with 10 tablets each. The Entresto recall covers several dosage strengths—24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg—with carton configurations varying from 10 to 100 counts. Each of these Novartis products is clearly marked with the company name, drug name, dosage, National Drug Code (NDC), lot number, and expiration date on both the carton and the blister card.

Simultaneously, Sandoz issued a recall for a wide array of their generic prescription drugs packaged in similar non-compliant blister cards. This list includes antibiotics like Azithromycin, Alzheimer’s treatments such as Donepezil ODT, antipsychotics including Haloperidol and Risperidone ODT, antidepressants like Imipramine HCl, and heart medications such as Isosorbide Dinitrate and Perphenazine. The Sandoz packages are identified by the "Sandoz" brand name, along with the drug name, dosage, NDC, and lot number printed on the packaging. For Sandoz products, consumers were advised to check specific lot numbers listed on their patient safety website, as the variety of medications and strengths was extensive, ranging from 3-tablet trial packs to 100-count boxes.

These recalled items were sold in pharmacies and medical supply stores across the United States. If you have these medications at home, it is important to look closely at the packaging rather than just the drug name, as the issue lies in the physical construction of the blister pack’s closure mechanism, which could potentially be opened by a child with relative ease compared to standard child-resistant containers. The recall was initiated on July 6, 2018, and remains relevant for anyone holding these specific lots, as the safety risk persists until the packages are secured or replaced.

The hazard, explained

To understand why this recall matters, we first need to look at what is supposed to happen with prescription medication packaging and what went wrong in this specific instance. Under the Poison Prevention Packaging Act, federal law requires that most prescription drugs be packaged in containers that are difficult for young children to open within a reasonable time, yet still accessible to adults who may have difficulty gripping or twisting standard caps. This "child-resistant" feature is not merely a suggestion; it is a critical safety barrier designed specifically to prevent accidental ingestion by curious toddlers and young children.

In this recall, the physical failure lies in the design of the blister packages provided by Sandoz and Novartis. Blister packs are typically composed of a plastic front and an aluminum foil back, sealed together around each individual tablet. While these packages are convenient for dosing and portability, they inherently lack the complex mechanical locking mechanisms found in traditional child-resistant bottles. The hazard here is that the specific blister cards included in this recall do not meet the rigorous performance standards required by law to resist opening by children under five years old. Essentially, the packaging failed its primary test: it could be opened or compromised by a child far too easily compared to the mandated safety benchmarks.

The mechanism of harm is straightforward but serious. When packaging fails to provide adequate resistance, a child can access the medication with little to no effort. Once inside reach, the tablets are readily available for ingestion. The recall notice cites one confirmed incident where a child ingested haloperidol from one of these non-compliant blister packs. Haloperidol is a potent antipsychotic medication, and any unintended dose can be dangerous. However, this risk applies to all drugs listed in the recall, not just that specific one. Accidental ingestion by children is a leading cause of poisoning emergencies. Even medications that are generally safe can become toxic if consumed in quantities intended for an adult, or if they interact poorly with a child’s developing physiology.

It is important to distinguish between the drug itself and its container. The medication inside these blister packs—whether it is Zofran, Entresto, Azithromycin, or others—is not inherently defective or contaminated. The problem is entirely about accessibility. A child-resistant package acts as a delay mechanism, giving parents or caregivers time to notice if a bottle has been tampered with and preventing immediate access. Without that barrier, the window for accidental exposure widens significantly. This is why the Consumer Product Safety Commission (CPSC) takes these failures so seriously: the packaging is the last line of defense between a curious child and potentially life-altering medical consequences.

For adults, especially those who are elderly or have limited dexterity, non-child-resistant packages might actually seem more appealing because they are easier to open. However, this convenience comes at the cost of safety for any household with young children. The failure to meet closure requirements means that these specific batches cannot be trusted to perform their essential protective function. Understanding this physical gap in security helps clarify why immediate action is necessary, even if you do not have small children in your home, as other visitors or younger siblings might pose a risk.

Who is most at risk

While this recall affects a wide variety of prescription medications ranging from heart drugs to antibiotics and psychiatric treatments, the primary group at immediate risk of harm in this specific scenario is young children. The core issue here is not the medication itself being dangerous for its intended patient, but rather the packaging failing to act as a barrier against curious hands. Children under the age of five are naturally exploratory and lack the cognitive ability to understand that blister packs contain potent substances. They often mimic adult behaviors, such as opening medicine bottles or tearing open foil packages, without realizing the consequences. Because these specific Novartis and Sandoz blister packages do not meet the rigorous child-resistant closure requirements mandated by the Poison Prevention Packaging Act, they can be opened with relative ease by a determined toddler. This is particularly concerning because children are more susceptible to poisoning than adults; their smaller body mass means that even a single tablet of certain medications can lead to severe toxicity or life-threatening symptoms.

The types of drugs involved in this recall highlight why the risk is so significant for any child who might gain access to them. The list includes Haloperidol, an antipsychotic medication used to treat conditions like schizophrenia and behavioral problems. If ingested by a child, Haloperidol can cause serious neurological side effects, including muscle stiffness, tremors, and difficulty breathing. It also includes Zofran (ondansetron), commonly prescribed for nausea. While it may seem benign compared to other drugs, an overdose in a young child can lead to heart rhythm abnormalities and sedation. Furthermore, the recall covers Entresto, a medication for heart failure. Although this is typically taken by older adults, its presence in households means that any child who finds it could suffer from dangerously low blood pressure or kidney issues.

Elderly patients are also part of the at-risk demographic, though their risk profile is different. Many of the individuals taking these medications, particularly those prescribed Entresto for heart failure or Risperidone for cognitive disorders, may live with caregivers or family members who have young grandchildren visiting frequently. The danger here is often indirect; a grandparent might believe the medication is safe because it came in a standard-looking box, unaware that the individual blister cards inside are not child-resistant. Additionally, elderly patients themselves may have diminished dexterity or vision, making them reliant on packaging that is easy to open but still secure. When packaging fails to balance these needs—being tough enough for an adult with arthritis but too weak against a child’s grip—it creates a vulnerable gap in home safety.

Finally, anyone who stores these medications in common areas of the home, such as on kitchen counters or in bathroom medicine cabinets that are visible to children, is at heightened risk. The recall notice itself cites an incident where a child successfully ingested Haloperidol from one of these blister packs, proving that the hazard is not theoretical but already occurring. Therefore, the most vulnerable individuals are those in households with unsupervised access to these specific drug lots. If you have young children in the home, or if elderly relatives visit frequently and may leave medications out, your household falls squarely into the high-risk category for this particular packaging failure.

How to tell if you have the recalled item

Identifying whether your medication is part of this recall requires a careful inspection of the packaging details. Because the issue involves specific blister packages from two major pharmaceutical manufacturers—Novartis and Sandoz—you need to look for distinct branding, National Drug Code (NDC) numbers, lot numbers, and expiration dates printed directly on the cartons and the individual blister cards. The recall affects a wide variety of prescription drugs, so simply knowing the drug name is not enough; you must verify the specific codes associated with these defective packages.

If your medication was manufactured by Novartis, look for the "Novartis" brand name printed on both the outer carton and the blister card. The packaging will also display the specific drug name (such as Zofran ODT® or Entresto®), the dosage strength, the NDC number, the lot number, and the expiration date. The affected Novartis products include Zofran ODT® in 4 mg and 8 mg strengths, and Entresto® in 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg strengths. For these items, check the NDC numbers carefully. For example, Zofran ODT® 4 mg includes NDCs 0078-0679-61 and 0078-0679-19. Entresto® products have various NDCs depending on the strength, such as 0078-0659-61 for the 24 mg/26 mg dose. You must also cross-reference the lot numbers listed in the recall notice, as only specific batches are affected. For Zofran ODT®, check for lot numbers 1657088 and 1641546. For Entresto®, look for lot numbers such as FX000005, FX000004, F0010, F0009, F0007, F0004, F0006, F0005, and others listed by expiration date.

If your medication was manufactured by Sandoz, look for the "Sandoz" brand name on the carton and blister card. The packaging will include the drug name, dosage, NDC number, and lot number. This recall covers a broad list of Sandoz products, including Azithromycin Tablets (250 mg), Donepezil ODT Tablets (5 mg and 10 mg), Haloperidol Tablets (0.5 mg through 10 mg), Imipramine HCl Tablets (25 mg and 50 mg), Isosorbide Dinitrate Tablets (10 mg and 20 mg), Naratriptan Tablets (2.5 mg), Ondansetron Tablets and ODT formulations, Perphenazine Tablets (2 mg, 4 mg, and 8 mg), and Risperidone ODT Tablets (0.5 mg through 4 mg). Each of these has specific NDC numbers you must verify against the recall list. For instance, Haloperidol 1 mg tablets have NDC 0781-1392-13, while Donepezil ODT 5 mg has NDCs 0781-5276-06 and 0781-5276-64. Lot numbers for Sandoz products are listed at www.us.sandoz.com/patients-customers/product-safety-notices, so you must visit that site to confirm if your specific lot is included.

To be certain, do not rely on memory or general appearance. Pick up the box and the blister pack. Locate the printed NDC number and lot number. Compare them directly to the lists provided above or on the official Novartis and Sandoz websites. If the numbers match exactly, your product is part of this recall. If you cannot find a lot number or if the NDC does not match any listed, your product is likely not affected, but you should still contact the manufacturer to confirm.

What to do — step by step

Your refund, repair, or replacement options

If you have identified one of the recalled prescription drug blister packages from Novartis or Sandoz, your immediate priority is securing the medication to prevent accidental ingestion by children. However, you are likely wondering what happens next regarding the product itself. It is important to understand that this specific recall does not involve a manufacturing defect in the medication’s efficacy or safety profile. The issue is strictly related to the packaging’s failure to meet child-resistant closure requirements mandated by law. Because the pills themselves remain safe and effective, the remedy provided by the companies differs from what you might expect for a defective physical good.

The official guidance from both Novartis and Sandoz is clear: you should continue to use the medication exactly as directed by your healthcare provider. The companies are not issuing automatic refunds, replacements, or repairs of the packaging in the traditional consumer product sense. Instead, they are advising consumers to take proactive steps to secure the blister cards in a location out of sight and reach of children until you have had a chance to speak with their support teams. This approach ensures that your treatment plan is not interrupted while the safety issue is addressed. If you are already on a different medication or have completed your course, you may not need any further action other than disposing of the unsafe packaging properly.

To get specific instructions tailored to your situation, you must contact Novartis or Sandoz directly. The recall notice provides a dedicated toll-free number for this purpose: 888-669-6682. Customer service representatives are available Monday through Friday from 8 a.m. to 8 p.m. Eastern Time, and on weekends (Saturday and Sunday) from 9 a.m. to 6 p.m. Eastern Time. During these calls, you can verify the specific lot numbers of your product and receive further instructions. They may advise you on how to return the packaging for proper disposal or provide details on any potential compensation or replacement programs if applicable to your region and specific product line.

If you prefer to communicate online, you can visit www.us.sandoz.com and navigate to the “Patients and Customers” section, then select “Product Safety Notices.” Alternatively, Novartis customers can go to www.pharma.us.novartis.com and click on the banner titled “Novartis recalls select product blister packs.” These digital channels provide access to the full list of recalled lot numbers and detailed FAQs. Please note that while the recall date was July 6, 2018, this information remains critical for anyone still holding onto these specific packages. Do not attempt to modify the packaging yourself or give it to someone else; always follow the official instructions provided by the manufacturer to ensure your safety and compliance with federal regulations.

What can happen if you ignore it

When a medication package fails to meet federal child-resistant standards, the primary danger is not that the medicine itself is inherently dangerous in normal circumstances, but rather that the barrier protecting it has become transparent to curious hands. You might look at a blister pack and see nothing unusual. The plastic may still be clear, the tablets intact, and the labeling easy to read. However, without the required child-resistant closure mechanism, a small child can open the package with relative ease. This is not a matter of strength alone; it is a matter of mechanics. Child-resistant packaging is specifically engineered to require a combination of actions—such as pushing down while twisting—that are developmentally difficult for children under five years old to coordinate. When that specific engineering is missing, the "lock" on the medicine cabinet effectively disappears.

The consequences of this oversight can be severe and immediate. Prescription medications are potent chemical compounds designed to alter bodily functions. For an adult, a dose measured in milligrams is carefully calculated. For a small child, even a fraction of that dose can be toxic. The recall facts note that the firms have already received one confirmed report of a child ingesting haloperidol from these affected blister packs. Haloperidol is a powerful antipsychotic medication that affects the central nervous system. Ingestion by a child can lead to serious symptoms such as extreme drowsiness, muscle spasms, difficulty breathing, and irregular heart rhythms. This single reported incident serves as a stark warning: the risk is not theoretical. It has already occurred.

If you continue to use these packages without securing them elsewhere, you are leaving your child vulnerable to accidental poisoning. Children are naturally exploratory; they do not understand that a tablet looks like candy or that a package labeled with their name is off-limits. They only see access. By ignoring the recall instructions to secure the medication in a high, locked, or out-of-sight place, you are effectively handing your child access to a substance that could require emergency medical intervention. The timeline for poisoning can be rapid. Once a tablet is removed from the blister and ingested, there is no time to search for the correct packaging type or call a pharmacist for advice. Immediate medical attention may be necessary to prevent long-term health impacts or worse.

Furthermore, relying on "normal" storage habits like leaving medication on a bathroom counter or in an unlocked cabinet becomes insufficient when the container itself does not provide protection. The failure of the blister pack means that standard household safety measures are no longer enough. You must assume that any child who can crawl or reach high shelves will be able to access these specific tablets. The goal is to prevent the ingestion event entirely, because once it happens, the outcome depends on how quickly you act and how much medication was consumed. Ignoring this recall leaves that critical safety gap wide open.

Staying safe: broader tips